Releaf® Announces Partnership with SOMAÍ Pharmaceuticals to Bring Innovative Cannabis Solutions to UK Patients NOTTINGHAM, ENGLAND / ACCESSWIRE / October 9, 2024 / Releaf , the UK's fastest-growing medical cannabis clinic, has joined forces with SOMAÍ Pharmaceuticals in an exclusive partnership aimed at revolutionizing patient care. Combining Releaf's industry-leading supply chain capabilities with SOMAÍ's advanced cannabis extracts, the collaboration is set to provide UK patients with exceptional, high-quality treatments. Tim Kirby - Releaf CEO (Left) & Michael Sassano - SOMAÍ CEO (Right) Releaf pride themselves on putting the patient experience first, and this partnership will grant Releaf patients exclusive access to SOMAÍ's Indica Essentials product line and its innovative mint-flavored range.
Designed to meet patients' needs and improve patient outcomes, SOMAÍ's products offer a range of THC/CBD ratios, terpene profiles, and genetics tailored to treat various conditions. Releaf demonstrates their commitment to patients with a vertically integrated supply chain to ensure uninterrupted treatment plans, including access to the only UK-grown cannabis-based medicinal product (CBPM). Releaf's Patient Charter further guarantees quality, consistency, and timely delivery, cementing its position as a trusted healthcare provider.
This new partnership will bolster Releaf's mission to provide best-in-class healthcare, offering timely, evidence-based treatment options for.
